Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973)

2019 ◽  
Vol 37 (2) ◽  
pp. 158-165 ◽  
Author(s):  
José Antonio March-Villalba ◽  
David Ramos-Soler ◽  
Pilar Soriano-Sarrió ◽  
David Hervás-Marín ◽  
Laura Martínez-García ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cyclin D1 ◽  
Progression Free Survival ◽  
Immunohistochemical Expression ◽  
Urothelial Bladder Cancer ◽  
Predictive Tool ◽  
Ki 67 ◽  
Free Survival ◽  
Urothelial Bladder

scholarly journals Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer

2020 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
Meftun Culpan ◽  
Turgay Turan ◽  
SidikaSeyma Ozkanli ◽  
Tulay Zenginkinet ◽  
Ozgur Kazan ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Immunohistochemical Expression ◽  
Urothelial Bladder Cancer ◽  
Ki 67 ◽  
Urothelial Bladder

scholarly journals Endothelin-1 indicates unfavorable prognosis in primary high-grade non-muscle-invasive urothelial bladder cancer

2021 ◽  
Vol 93 (2) ◽  
pp. 143-147
Author(s):  
Lampros Mitrakas ◽  
Stavros Gravas ◽  
Foteini Karasavvidou ◽  
Ioannis Zachos ◽  
Anastasios Karatzas ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Progression Free Survival ◽  
High Grade ◽  
Urothelial Bladder Cancer ◽  
Free Survival ◽  
Endothelin 1 ◽  
Bcg Therapy ◽  
Urothelial Bladder ◽  
Muscle Invasive ◽  
A Prospective Study

Objective: To conduct a prospective study of the potential prognostic role of endothelin-1 (ET-1) in a cohort of primary high-grade non-muscle-invasive urothelial bladder cancer patients, who were treated with adjuvant intravesical Bacillus Calmette-Guérin (BCG). Material and methods: Patients with primary high-grade nonmuscle- invasive urothelial bladder cancer, who received postoperatively induction and maintenance BCG therapy, were prospectively included. Recurrence and progression were histologically proven. Immunohistochemical staining for ET-1 was assessed. Epidemiological, pathological and clinical parameters as well as the expression of ET-1 in tumor specimens were statistically analyzed for recurrence, progression, recurrence-free survival (RFS) and progression-free survival (PFS). Results: ET-1 associates significantly with recurrence (p = 0.000), progression (p = 0.000), RFS (p = 0.000) and PFS (p = 0.000). The patient’s age is also significant for recurrence (p = 0.003, OR = 1.273 95% CI: 1.086-1.492) and RFS (p = 0.013). Conclusions: ET-1 seems to deteriorate prognosis in patients suffering from primary high-grade non-muscle-invasive urothelial bladder cancer, who are treated with adjuvant BCG instillations. Furthermore, the patient’s age associates with an increased likelihood for recurrence.

Molecular subtyping of metastatic urothelial bladder cancer.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 326-326
Author(s):  
Charlotte Ackerman ◽  
Sanjeev Mariathasan ◽  
Dorothee Nickles ◽  
Alfonso Gomez De Liano Lista ◽  
Akhila Ganeshi Wimalasingham ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Immune Therapy ◽  
Clinical Information ◽  
Progression Free Survival ◽  
The Cancer Genome Atlas ◽  
Urothelial Bladder Cancer ◽  
First Line ◽  
Metastatic Urothelial Cancer ◽  
Urothelial Bladder ◽  
Line Chemotherapy

326 Background: TCGA molecular sybtyping is established in metastatic urothelial bladder cancer (UBC). It remains unclear if it is of prognostic importance with chemotherapy in metastatic UBC. Data into immune therapy suggests TCGA subtyping is predictive to response. Methods: Archival formalin-fixed paraffin embedded (FFPE) tissue were analysed from 170 patients that had consented into a clinical trial (NCT00949455) after first line chemotherapy for metastatic disease. Gene expression levels were quantified by NanoString technology. Molecular subtypes were assigned according to The Cancer Genome Atlas (TCGA) subtypes. Clinical information was available for all patients and analysis on individual genes were explored. Results: 170 patients were analysed, 75% male. 107 (64%) patients received cisplatin based first-line chemotherapy, with 36% receiving carboplatin based regimen. Median overall survival (OS) was 15.73 months [95% CI: 13.87-17.58], and median progression free survival (PFS) was 10.71 months [95% CI: 8.97-12.45]. Samples were initially clustered into luminal (n=109) and basal (n=61) subtypes. Response to first line chemotherapy occurred in all subtypes but was shown to be significantly higher in the luminal subtype versus the basal subtype [58% vs 20%, p=0.01]. PFS was superior in luminal subtypes [11.8 months vs 8.9 months, p=0.005]. Exploratory analysis showed that luminal II subtype had the best outcome for OS [20.3 months, p=0.03] compared to the other subtypes. Outcomes with other genes including immune markers were explored. TCGA outcomes can be summarised in the table. Conclusions: In metastatic urothelial cancer, TCGA subclassifying influences outcome of patients post chemotherapy. [Table: see text]

scholarly journals Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer

2015 ◽  
Vol 68 (10) ◽  
pp. 819-824 ◽  
Author(s):  
Cédric Poyet ◽  
Lorenz Buser ◽  
Filip Roudnicky ◽  
Michael Detmar ◽  
Thomas Hermanns ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Connexin 43 ◽  
Cox Regression ◽  
Progression Free Survival ◽  
Cx43 Expression ◽  
Free Survival ◽  
Expression Levels ◽  
Urothelial Carcinomas ◽  
Urothelial Bladder ◽  
Muscle Invasive

ObjectivesTo evaluate the protein expression of connexin 43 (Cx43) in primary urothelial bladder cancer and test its association with the histopathological characteristics and clinical outcome.MethodsA tissue microarray containing 348 tissue samples from 174 patients with primary urothelial carcinomas of the bladder was immunohistochemically stained for Cx43. The intensity of staining was semiquantitatively evaluated (score 0, 1+, 2+), and the association with clinicopathological features was assessed. Univariable and multivariable analyses were performed to identify predictors for progression-free survival (PFS).ResultsMembranous Cx43 immunoreactivity was detected in 118 (67.8%) of 174 analysable urothelial carcinomas, of which 31 (17.8%) showed even a strong (score 2+) and mainly homogeneous staining. Strong expression levels of Cx43 (score 2+) were associated with higher tumour grade, multiplicity and increased proliferation (all p<0.05). In the subgroup of patients with stage pTa and pT1 bladder tumours (n=158), strong Cx43 expression (p<0.001), solid growth pattern (p<0.001) and increased Ki-67 proliferation fraction (p<0.05) were significantly associated with shorter PFS in an univariable Cox regression analysis. In multivariable Cox regression models, Cx43 immunoreactivity and histological growth pattern remained highly significant and adverse risk factors for PFS.ConclusionsThe expression levels of Cx43 are frequent in non-muscle invasive bladder cancer (NMIBC), with high expression levels being associated with poor prognosis. Routine assessment of Cx43 expression may improve the identification of high-risk NMIBC.

Sign in / Sign up

Export Citation Format

Share Document